Pelacarsen Trial Failure Might Change The Case For Investing In Ionis Stock (IONS)
Novartis and Ionis Pharmaceuticals' pelacarsen failed to reduce cardiovascular events in a Phase 3 trial, despite lowering lipoprotein(a) levels. This setback removes a potential revenue stream for Ionis, increasing pressure on its other late-stage RNA medicines. Analysts project $2.3B revenue and $222.2M earnings for Ionis by 2029, but the outcome raises execution risks and may extend the company's loss-making period.
How this was made
The 30-second read
Why it matters
The failure may shift investor focus to Ionis' rare‑disease and hereditary angioedema products, increasing volatility.
Market read
First‑report of a pivotal Phase 3 failure that directly impacts Ionis' revenue outlook and pipeline risk profile.
What to watch
Potential upside from partnership royalties and upcoming data on other pipeline assets could offset the loss.
Background
Ionis Pharmaceuticals co‑developed pelacarsen with Novartis; the trial outcome removes a projected cardiovascular revenue pillar.
Ticker impact
Phase 3 trial of pelacarsen failed to show cardiovascular event reduction, removing a potential revenue stream for Ionis.
Downward pressure likely in the near term, potential 5‑10% decline.
The trial result is a primary disclosure that directly affects future royalty revenue and raises execution risk for remaining pipeline.
Market effects
Biotech sector may see broader scrutiny of RNA‑based cardiovascular programs.
U.S. biotech investors likely to re‑price late‑stage pipeline risk.
Limited to companies with similar Lp(a) lowering strategies.
Counterpoint
If Ionis can accelerate approvals for its rare‑disease products, the setback may be priced in quickly.
Key entities
- companyIonis Pharmaceuticals
US‑listed biotech developing RNA therapeutics.
- companyNovartis
Partner in pelacarsen development.
